-

12:26:53 PM

BNGO Stock News

BNGO - Bionano Genomics Inc

05/17/22 4:05 PM

Nasdaq : BNGO

conferences

Bionano Genomics to Present at the 2022 H.C. Wainwright Global Investment Conference

Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced its

RHEA-AI

neutral

05/13/22 8:00 AM

Nasdaq : BNGO

Bionano Genomics Announces Participation at the 2022 American Cytogenomics Conference (ACC) and a User Spotlight Event at Augusta University, a Center of Excellence for OGM

For the first time at this conference, Bionano will exhibit all of its cytogenetic research solutions: OGM solutions, NxClinical software and laboratory services In a dedicated OGM scientific session, six presentations will illustrate the application of Bionano’s OGM in prenatal and postnatal

RHEA-AI

neutral

05/12/22 8:00 AM

Nasdaq : BNGO

Bionano Genomics Announces a Publication From the First Affiliated Hospital of Zhengzhou Highlighting the Utility of OGM

Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced

RHEA-AI

neutral

05/05/22 4:01 PM

Nasdaq : BNGO

earnings

Bionano Genomics Reports First Quarter 2022 Financial Results and Highlights Recent Business Progress

- 80% year-over-year revenue growth in Q1 2022 - Achieved all Q1 2022 ELEVATE! milestones - Strong balance sheet with $216.5 million in cash, cash equivalents, and available-for-sale securities at the end of Q1 2022 - Conference call today, May 5th, 2022 at 4:30 PM ET SAN DIEGEO, May 05, 2022

RHEA-AI

very positive

04/29/22 8:00 AM

Nasdaq : BNGO

Bionano Genomics Announces Peer-Reviewed Publication of NeuroSCORE Model to Predict and Prioritize Human Genes Contributing to Neurodevelopmental Disease

Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today

RHEA-AI

neutral

04/28/22 4:30 PM

Nasdaq : BNGO

conferencesearnings

Bionano Genomics to Report First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 5, 2022

Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, May 5th, 2022 at 4:30 p.m. Eastern Time to report financial results for the first quarter 2022 and to highlight recent corporate progress.

RHEA-AI

neutral

04/28/22 8:00 AM

Nasdaq : BNGO

management

TwinStrand Biosciences Expands Executive Team With Appointment of Goran Pljevaljcic as Chief Commercial Officer

TwinStrand Biosciences, Inc., the pioneer and developer of duplex sequencing, today announced the appointment of Goran Pljevaljcic, Ph.D. as Chief Commercial Officer. Dr. Pljevaljcic brings a successful track-record of commercial leadership in the genomics industry to TwinStrand, including experience building and managing clinical and research...

RHEA-AI

neutral

04/14/22 8:00 AM

Nasdaq : BNGO

Bionano Genomics Announces Issuance of Two U.S. Patents for Novel Methods that Expand Patent Protection for Uses of Nanochannel Arrays in Genome Analysis

Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today

RHEA-AI

neutral

04/07/22 8:00 AM

Nasdaq : BNGO

Bionano Genomics Announces Release of Version 6.2 of its NxClinical Software with Significant New Capabilities for Cancer Research Applications Including HRD Analysis

Version includes a powerful capability for genomic scar analysis for assessments of homologous recombination deficiency (HRD) that provides an efficient, consistent approach for analysis of tumor biomarkers used in pharmacogenomics and other cancer research SAN DIEGO, April 07, 2022 (GLOBE

RHEA-AI

neutral

04/06/22 8:00 AM

Nasdaq : BNGO

Bionano Genomics Announces Publication of a New Study Using OGM Combined with Multiple Analytical Methods Including Single-Cell Analysis as a Comprehensive Molecular Strategy to Characterize the Genomic Variation in B-cell Acute Lymphoblastic Leukemia

Bionano Genomics, Inc. ( BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

BNGO Data

IndustryTesting Laboratories
Websitebionanogenomics.com
CeoR. Erik Holmlin
Security nameBionano Genomics Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code3826
Employees147
Tags
- Health Technology
- Biotechnology
- Professional
- Scientific
- and Technical Services
- Testing Laboratories
Address9540 Towne Centre Dr Ste 100
StateCalifornia
CitySan Diego
Zip92121-1989
CountryUS
Phone18588887600

About Bionano Genomics Inc

Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano's Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns.